Results 91 to 100 of about 27,199 (232)

Immune features of graft‐derived mucosal‐associated invariant T cells predict gastrointestinal graft‐versus‐host disease

British Journal of Haematology, EarlyView.
Summary Gastrointestinal acute graft‐versus‐host disease (GI aGVHD) remains a major complication after allogeneic haematopoietic stem cell transplantation (allo‐HSCT), and early risk identification and intervention are essential for improving outcomes.
Gao Mengge, Cheng Rongqi, Kong Jun, Sun Yuqian, Wang Zhidong, Sun Hui, Chang Yingjun, Huang Xiaojun, Zhao Xiaosu   +8 more
wiley   +1 more source

Brain metastasis‐associated fibroblasts shape the tumour microenvironment to enhance cancer cell invasion

Brain Pathology, EarlyView.
Brain metastasis‐associated fibroblasts are active stromal components of the metastatic niche characterised by extracellular matrix remodelling and production of pro‐migratory mediators. They promote monocyte and cancer cell migration and enhance cancer cell invasion while having no growth‐promoting effect on cancer cells.
Barbora Výmolová, Lucie Pfeiferová, Tadeáš Karel Smetana, Petr Výmola, Nikola Ternerová, Michal Zubaľ, Michal Kolář, Jana Šáchová, Soňa Gyönyörová, Eva Balážiová, Magdalena Houdová Megová, Jakub Červenka, Helena Kupcová Skalníková, Michal Španko, Karel Smetana Jr., Lukáš Lacina, David Netuka, Robert Tomáš, Petr Bušek, Aleksi Šedo   +19 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Inducing Receptor Degradation as a Novel Approach to Target CC Chemokine Receptor 2 (CCR2)

International Journal of Molecular Sciences
CC chemokine receptor 2 (CCR2) has been linked to many inflammatory and immune diseases, making it a relevant drug target. Yet, all CCR2 antagonists developed so far have failed in clinical trials; thus, novel strategies are needed to target this receptor. Targeted protein degradation represents a novel approach to inhibit protein function by hijacking
Natalia V. Ortiz Zacarías, Sascha Röth, Jeremy D. Broekhuis, Daan van der Es, Kevin Moreau, Laura H. Heitman   +5 more
openaire   +3 more sources

KPNA2 Drives Immunosuppression in Ovarian Cancer via CCL2/CCR2‐Dependent MDSC Recruitment

Cancer Science, EarlyView.
KPNA2 drives intratumoral MDSC accumulation and immunosuppression in ovarian cancer via the NF‐κB/CCL2/CCR2 axis. Mechanistically, KPNA2 facilitates NF‐κB/p65 nuclear translocation and induces CCL2 transcription, recruiting MDSCs to establish an immunosuppressive microenvironment.
Qingli Li, Jitong Zhao, Lu Yang, Lin Li, Ce Bian, Tao Yi, Huiqiong Huang, Gang Zheng, Xiaojuan Lin   +8 more
wiley   +1 more source

Distribution of the CCR2-64I allele in three Brazilian ethnic groups

Genetics and Molecular Biology, 2003
CCR2 is a member of the superfamily of seven transmembrane domain G protein-coupled receptors, the largest receptor superfamily in the human genome. CCR2 acts as a receptor for MCP-1 (CC chemokine) and as a co-receptor for HIV-1 cell-target entry.
Acosta Angelina Xavier, Sampaio Rogério Grimaldi, Spínola Juliana Lima, Galvão-Castro Bernardo   +3 more
doaj  

Chemokine receptors CCR2 and CX3CR1 regulate viral encephalitis-induced hippocampal damage but not seizures. [PDF]

Proc Natl Acad Sci U S A, 2018
Käufer C, Chhatbar C, Bröer S, Waltl I, Ghita L, Gerhauser I, Kalinke U, Löscher W.   +7 more
europepmc   +1 more source